StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Equities research analysts at StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Eagle Pharmaceuticals stock opened at $0.56 on Wednesday. The company’s 50-day moving average is $0.69 and its 200-day moving average is $2.76. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $6.81.

Institutional Trading of Eagle Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Perceptive Advisors LLC bought a new stake in Eagle Pharmaceuticals in the 2nd quarter valued at $971,000. RBF Capital LLC increased its holdings in shares of Eagle Pharmaceuticals by 11.7% in the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after purchasing an additional 14,991 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Eagle Pharmaceuticals in the third quarter valued at about $453,000. DGS Capital Management LLC lifted its stake in shares of Eagle Pharmaceuticals by 44.9% during the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after buying an additional 22,239 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Eagle Pharmaceuticals during the 3rd quarter worth about $96,000. 85.36% of the stock is owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.